Tumor heterogeneity refers to the presence of a variety of distinct cell types within a tumor. High tumor heterogeneity is thought to contribute to breast cancer progression and metastasis, or spreading to other parts of ...
Aug 4, 2022
0
56
Liver cancer's rapid growth leads to a vulnerability in its energy-production and cell-building processes that may be potently exploited with a new combination-treatment strategy, according to a study from researchers at ...
Aug 2, 2022
0
72
Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study, published today in ...
Jun 21, 2022
0
285
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels from patient tumor samples, which contain both cancer and non-cancer cells. Using ...
Jun 13, 2022
0
28
A team of Yale-led researchers can now quantify the factors causing changes in the DNA that contribute most to cancer growth in tumors of most major tumor types.
Apr 27, 2022
0
412
Kathleen DelGiorno, assistant professor of cell and developmental biology, her lab and collaborators at the Salk Institute have discovered some of the specific signaling molecules involved in tumor progression in pancreatic ...
Apr 1, 2022
0
76
Stimulating the body's immune system to attack tumors is a promising way to treat cancer. Scientists are working on two complementary strategies to achieve that: taking off the brakes that tumors put on the immune system; ...
Jan 11, 2022
0
84
Researchers have identified a molecular mechanism that drives the progression of uveal melanoma (UM), an often lethal eye cancer in adults.
Sep 13, 2021
0
93
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal ...
Jul 23, 2021
0
155
Neoadjuvant immune checkpoint blockade (ICB) is a promising treatment for melanoma and other cancer types, and has recently been shown to provide a modest survival benefit for patients with recurrent glioblastoma. To improve ...
Jun 29, 2021
0
13
